Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey

Radiation Oncology

Yasumasa Nishimura²  Kenji Nemoto^1,13  Yasuo Yoshioka^1,18  Mitsuhiro Takemoto⁸  Hideya Yamazaki⁵  Yoshihiko Manabe⁹  Makoto Takayama^1,10  Katsuyuki Karasawa³  Yoshinori Ito⁶  Takashi Uno^1,16  Takashi Kosugi^1,11  Hirofumi Asakura^1,14  Tetsuro Tamamoto¹  Naoto Kanesaka⁷  Toshiya Maebayashi^1,12  Nobue Uchida^1,15  Hiroshi Onishi⁴  Hirobumi Oikawa^1,17  Kazuhiko Ogawa^1,18  Fumiaki Isohashi^1,18 

[1] Department of Radiation Oncology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan;Department of Radiation Oncology, Kinki University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan;Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, 18-22, Honkomagome 3chome, Bunkyo-ku, Tokyo, 113-8677, Japan;Department of Radiology, University of Yamanashi, 1110, Shimogato Chuo, Yamanashi, 409-3898, Japan;Department of Radiology, Kyoto Prefectural University of Medicine, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan;Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan;Department of Radiology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuju-ku, Tokyo, 160-8402, Japan;Department of Radiology, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan;Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho-cho, Mizuho-ku Nagoya, Aichi, 467-8601, Japan;Department of Radiology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan;Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu city, Shizuoka, 431-3192, Japan;Department of Radiology, Nihon University School of Medicine, 30-1, Ohyaguchi-Kamimachi, Itabashi-ku, Tokyo, 173-8610, Japan;Department of Radiation Oncology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan;Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi Town, Shizuoka, 411-8777, Japan;Present affiliation: Department of Radiation Oncology, Tottori Prefectural Central Hospital, 730 Etsu, Tottori-shi, Tottori, 680-0901, Japan;Department of Radiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chiba, 260-8677, Japan;Department of Radiology, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan;Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D-10) Yamadaoka, Suita, Osaka, 565-0871, Japan

关键词: Palliative;    Adjuvant;    Chemotherapy;    Radiotherapy;    Biliary tract cancer;   

Others  :  1154307
DOI  :  10.1186/1748-717X-8-76

 received in 2012-12-21, accepted in 2013-03-23,  发布年份 2013

【 摘 要 】

Background

The patterns of radiotherapy (RT) practice for biliary tract cancer (BTC) in Japan are not clearly established.

Methods

A questionnaire-based national survey of RT used for BTC treatment between 2000 and 2011 was conducted by the Japanese Radiation Oncology Study Group. Detailed information was collected for 555 patients from 31 radiation oncology institutions.

Results

The median age of the patients was 69 years old (range, 33–90) and 81% had a good performance status (0–1). Regarding RT treatment, 78% of the patients were treated with external beam RT (EBRT) alone, 17% received intraluminal brachytherapy, and 5% were treated with intraoperative RT. There was no significant difference in the choice of treatment modality among the BTC subsites. Many patients with EBRT were treated with a total dose of 50 or 50.4 Gy (~40%) and only 13% received a total dose ≥60 Gy, even though most institutions (90%) were using CT-based treatment planning. The treatment field consisted of the primary tumor (bed) only in 75% of the patients. Chemotherapy was used for 260 patients (47%) and was most often administered during RT (64%, 167/260), followed by after RT (63%, 163/260). Gemcitabine was the most frequently used drug for chemotherapy.

Conclusions

This study established the general patterns of RT practice for BTC in Japan. Further surveys and comparisons with results from other countries are needed for development and optimization of RT for patients with BTC in Japan.

【 授权许可】

   
2013 Isohashi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Park SW, Park YS, Chung JB, Kang JK, Kim KS, Choi JS, Lee WJ, Kim BR, Song SY: Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroentelogy 2004, 51:1612-1618.
• [2]Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012, 42:139-147.
• [3]Bonet Beltràn M, Allal AS, Gich I, Solé JM, Carrió I: Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev 2012, 38:111-119.
• [4]Shinohara ET, Mitra N, Guo M, Metz JM: Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009, 74:1191-1198.
• [5]Nishimura Y, Koike R, Ogawa K, Sasamoto R, Murakami Y, Itoh Y, Negoro Y, Itasaka S, Sakayauchi T, Tamamoto T: Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese radiation oncology study group (JROSG) survey. Int J Clin Oncol 2012, 17:48-54.
• [6]Ogawa K, Ito Y, Karasawa K, Ogawa Y, Onishi H, Kazumoto T, Shibuya K, Shibuya H, Okuno Y, Nishino S, Ogo E, Uchida N, Karasawa K, Nemoto K, Nishimura Y, JROSG Working Subgroup of Gastrointestinal Cancers: Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey. Int J Radiat Oncol Biol Phys 2010, 77:743-750.
• [7]Shibuya H, Tsujii H: The structural characteristics of radiation oncology in Japan in 2003. Int J Radiat Oncol Biol Phys 2005, 62:1472-1476.
• [8]Teshima T, Numasaki H, Shibuya H, Nishio M, Ikeda H, Ito H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Nagata Y, Masaki H, Nishimura T, Yamada S, Japanese Society of Therapeutic Radiology and Oncology Database Committee: Japanese structure of radiation oncology in 2005 based on institutional stratification of patterns of care study. Int J Radiat Oncol Biol Phys 2008, 72:144-152.
• [9]Alden ME, Mohiuddin M: The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994, 28:945-951.
• [10]Lu JJ, Bains YS, Abdel-Wahab M, Brandon AH, Wolfson AH, Raub WA, Wilkinson CM, Markoe AM: High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J 2002, 8:74-78.
• [11]Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59:445-453.
• [12]Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N: Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 2003, 57:1357-1365.
• [13]Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003, 98:1689-1700.
• [14]Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C, Janjan NA: Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002, 53:969-974.
• [15]Brunner TB, Schwab D, Meyer T, Sauer R: Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 2004, 180:751-757.
• [16]Shin HS, Seong J, Kim WC, Lee HS, Moon SR, Lee IJ, Lee KK, Park KR, Suh CO, Kim GE: Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003, 57:105-112.
• [17]Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS: Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010, 10:492. BioMed Central Full Text
• [18]Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG: Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009, 73:148-153.
• [19]Czito BG, Anscher MS, Willett CG: Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006, 20:873-884.
• [20]Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.